Drug
Agalsidase beta (GZ419828)
Agalsidase beta (GZ419828) is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_4
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Active, not recruiting1
Completed1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (33.3%)
Phase 42 (66.7%)
Trials by Status
active_not_recruiting133%
completed133%
withdrawn133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_3
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548
completedphase_4
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
NCT06019728
withdrawnphase_4
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
NCT04143958
Clinical Trials (3)
Showing 3 of 3 trials
NCT05280548Phase 3
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT06019728Phase 4
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
NCT04143958Phase 4
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3